The TERISA study evaluated the efficacy and safety of Ranexa in patients with a history of type 2 diabetes mellitus (T2DM), coronary artery disease (CAD), and chronic stable angina that remained symptomatic despite treatment with 1 or 2 antianginal agents.1
Ranexa: 11% fewer angina episodes vs placebo over weeks 2 through 8 of treatment (incidence density ratio=0.89, P=0.008)
*Weekly angina frequency for Ranexa compared with placebo using least squares mean negative binomial model.
When analyzed by arithmetic mean to determine the change from baseline, the results showed that the reduction in angina frequency over weeks 2-8 was 26% for placebo and 34% for Ranexa.2,3
(Baseline average angina frequency doses, minus the average from weeks 2 through 8) x 100/baseline average.See below for TERISA trial design and baseline characteristics.
Ranexa: 17% less sublingual nitroglycerin use than placebo over weeks 2 through 8 of treatment (incidence density ratio n=0.83, P=0.003)
†Weekly sublingual nitroglycerin use for Ranexa compared with placebo using least-squares-mean negative binomial model.
The percent reduction in sublingual nitroglycerin consumption from baseline over weeks 2-8 was 21% for placebo and 32% for Ranexa.2,3
(Baseline average nitroglycerin doses, minus the average from weeks 2 through 8) x 100/baseline average.See below for TERISA trial design and baseline characteristics.
The most common serious and nonserious adverse events reported in the TERISA clinical trial.‡1
Safety analysis includes patients who took any dose of study drug.
|Age (yrs)||64.2 ± 8.4||63.2 ± 8.5|
|Current smoking (%)||16.6||15.4|
|Prior myocardial infarction (%)||72.7||75.4|
|Prior angioplasty (%)||38.8||42.7|
|Prior bypass graft surgery (%)||18.9||18.2|
|Duration of diabetes (yrs)||7.7 ± 7.0||7.2 ± 6.7|
|HbA1c (%)||7.3 ± 1.5||7.3 ± 1.5|
|Glucose-lowering medication (%)||92.7||93.3|
|Angianginal medications (%)|
|On 1 (%)||55.7||56.1|
|On 2 (%)||44.3||43.9|
|Calcium channel blockers (%)||30.8||26.8|
|Long-acting nitrates (%)||32.5||34.8|
|Antiplatelets agents (%)||86.5||89.8|
|Baseline heart rate (bmp)||70.0 ± 9.8||69.0 ± 8.0|
|Baseline systolic blood pressure (mm Hg)||131.0 ± 11.3||131.0 ± 11.0|
|Baseline diastolic blood pressure (mm Hg)||79.0 ± 7.8||79.0 ± 7.7|
ACE=angiotensin-converting enzyme; ARB=angiotensin II receptor blocker; BID=twice a day.
Learn about safety data from the Ranexa clinical trials, including use in special populations.Review Safety & Tolerability
Is the burden of angina under-recognized in your patients? Encourage open communication to help accurately assess the presence and frequency of your patients’ angina.
Learn more about prevalence, symptom reporting, and recurrence post-PCI.Understand the Challenges
Ranexa Connect™ is a financial assistance resource for patients with a Ranexa prescription.
Ranexa Connect is pleased to announce iAssist, a program to help get your patients started on Ranexa faster. The program offers online patient enrollment, electronic signatures, as well as real-time pharmacy benefit check and eligibility for financial assistance.Get Started Now
1. Kosiborod M, Arnold SV, Spertus JA, et al. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). J Am Coll Cardiol. 2013;61(20):2038-2045.
2. Data on file, Gilead Sciences, Inc.
3. Kosiborod M, Arnold SV, Spertus JA, et al. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). Appendix. J Am Coll Cardiol. 2013;61(Online Appendix 1):S10.